Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (15)

2022

  1. Histopathology of Dermatologic Complications of Tattoos

    American Journal of Dermatopathology, Vol. 44, Núm. 9, pp. 632-649

  2. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1

  2. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity

    Cardiovascular research, Vol. 117, Núm. 4, pp. 1132-1143

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

  4. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity

    Journal of the American College of Cardiology, Vol. 73, Núm. 7, pp. 779-791

  5. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition after Myocardial Infarction

    Circulation Research, Vol. 121, Núm. 4, pp. 439-450

  3. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients

    Breast, Vol. 33, pp. 8-13

2009

  1. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314